[8-K] GE HealthCare Technologies Inc. Reports Material Event

Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) – Form 144 filing. Director-level insider Paul Mahon has filed to sell an additional 11,000 common shares on or about 24 Jul 2025 through Morgan Stanley Smith Barney. At the indicated market value of $3.35 million, the block equals roughly 0.024 % of the 45.1 million shares outstanding.

The filing also discloses recent insider dispositions totaling 66,000 shares over the past three months, generating $19.56 million in gross proceeds. Including the planned sale, Mahon’s cumulative dispositions would reach 77,000 shares, or ~0.17 % of shares outstanding. All shares derive from stock-option exercises paid in cash.

No company financials are provided; the document is strictly a notice required by Rule 144. While the absolute share count is modest, continued insider selling may attract investor attention. The filing confirms regulatory compliance and does not assert possession of undisclosed adverse information.

Positive

• Regulatory compliance: Filing under Rule 144 signals adherence to disclosure requirements, mitigating legal risk.

Negative

• Continued insider selling: Aggregate 77,000 shares scheduled or sold in three months may be perceived as a bearish sentiment indicator.
• Lack of offsetting insider buys: No purchases disclosed to counterbalance the disposals.

Insights

Securities Analyst

TL;DR: Small—0.024 %—insider sale; ongoing disposals worth $23 m YTD could be viewed as mild negative but not financially material.

The proposed 11,000-share sale adds to a 66,000-share disposal history over the last quarter. Even combined, the 77,000 shares equal just 0.17 % of UTHR’s float, limiting dilution or ownership impact. Insider sales may hint at reduced personal conviction, yet the transactions stem from option exercises, a common liquidity event. No operational data accompany the notice, so fundamental outlook remains unchanged. Overall impact: neutral-to-slightly negative; likely minimal share-price effect absent broader context.

0001932393false00019323932025-07-232025-07-2300019323932025-05-282025-05-28

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 23, 2025

GE HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41528

88-2515116

(State or other jurisdiction of incorporation)

(Commission  File Number)

(IRS Employer Identification No.)

500 W. Monroe Street,

Chicago,

IL

60661

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code) (833) 735-1139

______________________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.01 per share

GEHC

The Nasdaq Stock Market LLC

			Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
			Emerging growth company			☐
			If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.			☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 23, 2025, Lloyd W. Howell, Jr. notified GE HealthCare Technologies Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective immediately. Mr. Howell’s resignation from the Board was not a result of any disagreement on a matter related to the Company’s operations, policies, or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GE HealthCare Technologies Inc.
						(Registrant)
Date: July 24, 2025						/s/ Frank R. Jimenez
						Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory)

FAQ

How many United Therapeutics (UTHR) shares are being sold under this Form 144?

11,000 common shares are slated for sale.

What is the estimated market value of the planned UTHR share sale?

Approximately $3.35 million based on the filing’s stated price.

How significant is the sale relative to shares outstanding?

The block equals about 0.024 % of the 45.1 million shares outstanding, a minor portion of float.

Have there been other recent insider sales by the same filer?

Yes. Mahon has already sold 66,000 shares since May 2025, generating roughly $19.56 million in proceeds.

What is the nature of the shares being sold?

All shares originate from stock-option exercises paid for in cash.

Which broker is handling the transaction?

Morgan Stanley Smith Barney LLC, Executive Financial Services desk.